Almost three years after the merger of Widex and Sivantos, WSA enters a new phase

In March 2022, WSA will celebrate its third anniversary of the merger that brought Widex and Sivantos together. Today, CEO Eric Bernard talks about "changing gears" to increase coworkers' well-being and engagement. Paradoxically, the Covid-19 pandemic might have helped accelerate this process, he says.

"We're almost three years after the merger, so we're no longer talking about synergies," says Eric Bernard, CEO of WSA

In less than three months, hearing giant WS Audiology can celebrate the three-year anniversary of the day then-companies Widex and Sivantos merged into one, under the name WSA.

Though the Covid-19 pandemic has been a fact of life for most of its lifetime, WSA is now at a place where it can announce that the integration of the two companies is largely complete, according to the company's CEO Eric Bernard.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs